IRON Insider Trading

Insider Ownership Percentage: 4.24%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $25,068,128.17

Disc Medicine Insider Trading History Chart

This chart shows the insider buying and selling history at Disc Medicine by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Disc Medicine Share Price & Price History

Current Price: $42.17
Price Change: Price Increase of +1.17 (2.85%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for IRON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$42.17Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Disc Medicine (NASDAQ:IRON)

83.70% of Disc Medicine stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IRON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$908kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1B$0$1BTotal InflowsTotal Outflows
Disc Medicine logo
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
Read More on Disc Medicine

Today's Range

Now: $42.17
Low: $40.69
High: $42.46

50 Day Range

MA: $49.74
Low: $34.28
High: $56.92

52 Week Range

Now: $42.17
Low: $25.64
High: $68.73

Volume

347,423 shs

Average Volume

347,470 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Who are the company insiders with the largest holdings of Disc Medicine?

Disc Medicine's top insider shareholders include:
  1. Venture Fund X LP Atlas (Major Shareholder)
  2. Holdings A/S Novo (Major Shareholder)
  3. Kevin Bitterman (Director)
  4. Orbimed Advisors Llc (Director)
  5. Mona Ashiya (Director)
  6. John D Quisel (CEO)
  7. Jean M Franchi (CFO)
  8. Pamela Stephenson (Insider)
  9. Jonathan Yen-Wen Yu (COO)
  10. William Jacob Savage (Insider)
  11. Rahul Khara (Insider)
  12. Brian Richard Macdonald (Insider)
  13. Joanne Bryce (CFO)
  14. Rahul Khara (General Counsel)
  15. William Richard White (Director)
Learn More about top insider investors at Disc Medicine.

Who are the major institutional investors of Disc Medicine?

Disc Medicine's top institutional investors include:
  1. Rhumbline Advisers — 0.09%
  2. SG Americas Securities LLC — 0.04%
  3. GAMMA Investing LLC — 0.04%
Learn More about top institutional investors of Disc Medicine stock.

Which institutional investors are buying Disc Medicine stock?

During the last quarter, IRON stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. SG Americas Securities LLC
  3. Rhumbline Advisers